Delcath Systems, Inc., an interventional oncology company, has announced the approval of equity awards for eleven new employees who began their roles in March and April 2025. As part of the company's 2023 Inducement Plan, these grants allow the purchase of 111,000 shares of Delcath's common stock. Approved by the Compensation Committee, the stock options carry an exercise price of $12.04, reflecting the closing price on April 30, 2025. The vesting schedule stipulates that one-third of the options will vest after one year, with the remaining options vesting in equal monthly installments over the subsequent two years, contingent on continued employment. The options have a ten-year term. These moves align with Nasdaq Listing Rule 5635(c)(4).